Autoimmune Polyglandular Syndrome Type II: Case Report
DOI:
https://doi.org/10.55204/trc.v3i1.e127Keywords:
Addison's disease, Autoimmune disease, Hashimoto's disease, Autoimmune polyendocrinopathies, Case reportAbstract
Abstract: The autoimmune polyglandular syndrome type II, constitutes a clinical rarity and complex because it causes the failure of two or more endocrine glands and damage to non-endocrine organs, which makes it a serious condition, of which, until now, its cause is not completely known, however, its etiopathogenesis focuses on autoimmune and genetic factors, Its etiopathogenesis is centered on autoimmune and genetic factors, it is difficult to diagnose due to the lack of information and a standardized protocol, the clinical manifestations depend on the affected gland, it requires a complex treatment and its inadequate management can result in the death of the patient. This is the reason for the relevance of this case report.
This is a 69-year-old female patient of Ecuadorian nationality, who has a history of gastritis, osteoporosis and osteoarthritis, who comes to the medical center for presenting hyperpigmentation of skin and mucous membranes, is referred to the endocrinology department where she is requested values of adrenocorticotropic hormone, the results showed an elevated adrenocorticotropic hormone, years later she was diagnosed with Hashimoto's thyroiditis, so an autoimmune polyglandular syndrome type II was suspected, due to the association of these two pathologies, the diagnosis was corroborated and the corresponding therapeutic follow-up was performed. The relevance of the case lies in its low incidence and in the diagnostic process, suspected in the context of a pathology unrelated to the underlying endocrine autoimmune pathology.
Keywords:Addison's disease, Autoimmune disease, Hashimoto's disease, Autoimmune polyendocrinopathies, Case report.
Downloads
References
Stahn B, Scheit L. [The Schmidt’s Syndrome]. Dtsch Med Wochenschr 1946. 2019;144(24):1741-4. DOI: 10.1055/a-0875-4538 DOI: https://doi.org/10.1055/a-0875-4538
Anyfantakis D, Symvoulakis E, Vourliotaki I, Kastanakis S. Schmidt’s syndrome presenting as a generalised anxiety disorder: a case report. J Med Life. 2013;6(4):451-3.
Kahaly GJ. Polyglandular Autoimmune Syndrome Type II. Presse Médicale. 2012;41(12, Part 2):e663-70. DOI: 10.1016/j.lpm.2012.09.011 DOI: https://doi.org/10.1016/j.lpm.2012.09.011
Kahaly GJ, Frommer L. Autoimmune polyglandular diseases. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101344. DOI: 10.1016/j.beem.2019.101344 DOI: https://doi.org/10.1016/j.beem.2019.101344
Karamifar H, Dalili S, Karamizadeh Z, Amirhakimi G, Dalili H. Autoimmune Polyglandular Syndrome Type 2: An Unusual Presentation. Acta Med Iran. 2010;196-7.
Urbina A, Rodríguez E, Aquino J, Ramírez L, Arenas R, Zacarías R, et al. Síndrome poliglandular autoinmunitario tipo II (síndrome de Schmidt): enfermedad de Addison y tiroiditis de Hashimoto asociado con vitíligo. Med Interna México. 2017;33(2):241-5.
Gupta AN, Nagri SK. Schmidt’s syndrome – Case report. Australas Med J. 2012;5(6):292-5. DOI: https://doi.org/10.4066/AMJ.2012.987
Barreda-Velit C, Salcedo-Pereda R, Ticona J. Schmidt’s syndrome: a difficult diagnosis in the Latin American context. Rev Medica Inst Mex Seguro Soc. 2018;56(2):189-93.
Polyglanduläres Autoimmunsyndrom Typ 2 - Altmeyers Enzyklopädie - Fachbereich Innere Medizin. 2021
Bakkour A, Zakkor M, Taha Khairy L, Horo R, Mohammed E, Alhussein H. Autoimmune polyglandular syndrome type 2: A case report. Ann Med Surg. 2022;78:103742. DOI: 10.1016/j.amsu.2022.103742 DOI: https://doi.org/10.1016/j.amsu.2022.103742
Lenz M. Polyglanduläres Autoimmunsyndrom Typ II (PAS II). 2021.
Dorin R, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003;139(3):194-204. DOI: 10.7326/0003-4819-139-3-200308050-00009. DOI: https://doi.org/10.7326/0003-4819-139-3-200308050-00009
Schatz D, Winter W. Autoimmune polyglandular syndrome. II: Clinical syndrome and treatment. Endocrinol Metab Clin North Am. 2002;31(2):339-52. DOI: 10.1016/s0889-8529(01)00012-3. DOI: https://doi.org/10.1016/S0889-8529(01)00012-3
Fernández Miró M, Colom Comí C, Godoy Lorenzo R. Autoinmune polyendocrinopathy. Med Clin (Barc). 2021;157(5):241-246. DOI: 10.1016/j.medcli.2021.02.004. DOI: https://doi.org/10.1016/j.medcle.2021.08.006
Schulz L, Hammer E. Autoimmune polyglandular syndrome type II with co-manifestation of Addison's and Graves' disease in a 15-year-old boy: case report and literature review. J Pediatr Endocrinol Metab. 2020;33(4):575-578. DOI: 10.1515/jpem-2019-0506. DOI: https://doi.org/10.1515/jpem-2019-0506
Kraus A, Penna-Martinez M, Shoghi F, Meyer G, Badenhoop K. Monocytic Cytokines in Autoimmune Polyglandular Syndrome Type 2 Are Modulated by Vitamin D and HLA-DQ. Front Immunol. 2020;11:583709. DOI: 10.3389/fimmu.2020.583709. DOI: https://doi.org/10.3389/fimmu.2020.583709
Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164(5):2405-11. DOI: 10.4049/jimmunol.164.5.2405. DOI: https://doi.org/10.4049/jimmunol.164.5.2405
Boonstra A, Barrat F, Crain C, Heath V, Savelkoul H, O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001;167(9):4974-80. DOI: 10.4049/jimmunol.167.9.4974. DOI: https://doi.org/10.4049/jimmunol.167.9.4974
Husebye E, Anderson M. Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis. Immunity. 2010;32(4):479-87. DOI: 10.1016/j.immuni.2010.03.016. DOI: https://doi.org/10.1016/j.immuni.2010.03.016
Betterle, C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune Adrenal Insufficiency and Autoimmune Polyendocrine Syndromes: Autoantibodies, Autoantigens, and Their Applicability in Diagnosis and Disease Prediction. Endocrine Reviews, 2002;23(3), 327–364. DOI:10.1210/edrv.23.3.0466 DOI: https://doi.org/10.1210/edrv.23.3.0466
Kahaly, G.J.; Frommer, L.; Schuppan, D. Celiac Disease and Glandular Autoimmunity. Nutrients. 2018;(10): 814. DOI: https://doi.org/10.3390/nu10070814 DOI: https://doi.org/10.3390/nu10070814
Nederstigt C, Uitbeijerse B, Janssen L, Corssmit, E, Koning E, Dekkers O. Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis, European Journal of Endocrinology. 2019;180(2):135-144. DOI: https://doi.org/10.1530/EJE-18-0515
Wang X, Ping F, Qi C, Xiao X. Delayed diagnosis with autoimmune polyglandular syndrome type 2 causing acute adrenal crisis: A case report. Medicine (Baltimore). 2016;95(42):e5062. DOI: 10.1097/MD.0000000000005062. DOI: https://doi.org/10.1097/MD.0000000000005062
Bayless D, Caldarera T, Harirah H. Autoimmune polyglandular syndrome type 2 in pregnancy: a case report and review of the literature. 2022. https://doi.org/10.1515/crpm-2020-0058 DOI: https://doi.org/10.1515/crpm-2020-0058
Gaba N, Gaba S, Singla M, Gupta M. Type 2 Autoimmune Polyglandular Syndrome Presenting with Hyperpigmentation and Amenorrhea. 2020 DOI: https://doi.org/10.7759/cureus.7772
Betterle C, Lazzarotto F, Presotto F, Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?, Clinical and Experimental Immunology. 2004;137(2):225–233. DOI: 10.1111/j.1365-2249.2004.02561.x DOI: https://doi.org/10.1111/j.1365-2249.2004.02561.x
Hoener K, Sharma T. Type II polyglandular autoimmune syndrome: a case of Addison’s disease precipitated by use of levothyroxine. BMJ Case Rep. 21 de agosto de 2019;12(8):e230760. DOI: 10.1136/bcr-2019-230760. DOI: https://doi.org/10.1136/bcr-2019-230760
Martins S, Venade G, Teixeira M, Olivério J, Machado J, Marques J, et al. Autoimmune Polyglandular Syndrome type 2. Rev Assoc Medica Bras 1992. diciembre de 2019;65(12):1434-7. DOI: 10.1590/1806-9282.65.12.1434 DOI: https://doi.org/10.1590/1806-9282.65.12.1434
Bain A, Stewart M, Mwamure P, Nirmalaraj K. Addison’s disease in a patient with hypothyroidism: autoimmune polyglandular syndrome type 2. BMJ Case Rep. 3 de agosto de 2015;bcr2015210506. DOI: 10.1136/bcr-2015-210506 DOI: https://doi.org/10.1136/bcr-2015-210506
Shi Y, Shen M, Zheng X, Chen Y, Zhao R, Gu Y, Yang T. ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management. J Clin Endocrinol Metab. 2020;105(12):dgaa553. DOI: 10.1210/clinem/dgaa553. DOI: https://doi.org/10.1210/clinem/dgaa553
Rams A, Żółciński M, Zastrzeżyńska W, Polański S, Serafin A, Wilańska J, Musiał J, Bazan-Socha S. Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab. J Asthma. 2018;55(12):1384-1386. DOI: 10.1080/02770903.2017.1414239 DOI: https://doi.org/10.1080/02770903.2017.1414239
Caprio M, Infante M, Calanchini M, Mammi C, Fabbri A. Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects. Eat Weight Disord. 2017;22(1):27-41. DOI: 10.1007/s40519-016-0312-6. DOI: https://doi.org/10.1007/s40519-016-0312-6
Saif A, Assem M. Premature ovarian failure could be an alarming sign of polyglandular autoimmune dysfunction. Endocr Regul. 2017;51(2):114-116. DOI: 10.1515/enr-2017-0011. DOI: https://doi.org/10.1515/enr-2017-0011
Yanachkova V, Chaveeva P, Staynova R, Milcheva R. Autoimmune Polyglandular Syndrome Type 2 and Pregnancy. Folia Med (Plovdiv). 2020;62(2):408-411. doi: 10.3897/folmed.62.e48580. PMID: 32666756. DOI: https://doi.org/10.3897/folmed.62.e48580
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Ariana Lisseth Vázquez López, Iván Andrés Rosero Viteri, Debbie Noelia Tebanta Albán, Mónica Fernanda Angamarca Coello, Edgar José León Astudillo
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the moral and patrimonial rights of their works. They only give to the magazine Tesla Revista Científica the right to the first publication of this. Since Tesla Revista Científica is an open access publication, readers can fully or partially reproduce its content as long as they properly credit the corresponding authors and the journal itself. Tesla Revista Científica undertakes not to make commercial use of the texts it receives and/or publishes.
Our journal is governed by the international policies SHERPA/RoMEO: Green journal: They allow the self-archiving of both the pre-print (draft of a paper) and the post-print (the version corrected and reviewed by peers) and even the final version ( layout as it will be published in the journal).
See also "Copyright and licences".
